+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recent Advances in Healthcare Diagnostics and Therapies

  • ID: 4327573
  • Report
  • June 2017
  • Region: Global
  • 15 pages
  • Frost & Sullivan
This edition of the Genetic Technology TOE depicts new life sciences trends across diagnostics and therapeutics. Clinical trial results for several indications using antibody therapy are illustrated. Innovations in engineered 3D heart tissue and metabolome analyses for drug testing are also depicted. The corresponding clinical trial scenario is exhibited, along with the corresponding industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
Innovations in Healthcare Diagnostics and Therapeutics
  • Encouraging Phase III Results for Eli Lilly's Antibody Therapy for Migraine
  • Engineering 3D Heart Tissue for Enabling Effective Drug Testing
  • Enabling Comprehensive Analysis of the Metabolome
  • Enhanced Clinical Decisions through Comprehensive Diagnostics
Clinical Trial Analysis and Industry Interactions
  • Clinical Trial Analysis
  • Industry Interactions
Note: Product cover images may vary from those shown